Last reviewed · How we verify
Gan & Lee Insulin Aspart
At a glance
| Generic name | Gan & Lee Insulin Aspart |
|---|---|
| Also known as | NovoRapid® EU, NovoLog® US |
| Sponsor | Gan and Lee Pharmaceuticals, USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males (PHASE1)
- Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gan & Lee Insulin Aspart CI brief — competitive landscape report
- Gan & Lee Insulin Aspart updates RSS · CI watch RSS
- Gan and Lee Pharmaceuticals, USA portfolio CI